Suppr超能文献

韦格纳肉芽肿中与卡氏肺孢子虫肺炎相关的因素。

Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis.

作者信息

Godeau B, Mainardi J L, Roudot-Thoraval F, Hachulla E, Guillevin L, Huong Du L T, Jarrousse B, Remy P, Schaeffer A, Piette J C

机构信息

Service de Médecine Interne, Hôpital Henri Mondor, Créteil, France.

出版信息

Ann Rheum Dis. 1995 Dec;54(12):991-4. doi: 10.1136/ard.54.12.991.

Abstract

OBJECTIVE

To determine the factors associated with the occurrence of Pneumocystis carinii pneumonia (PCP) in Wegener's granulomatosis (WG).

METHODS

We retrospectively compared a group of 12 patients with WG and PCP (PCP group), with 32 WG patients without PCP followed over the same period in the same centres (control group).

RESULTS

The mean delay of onset of PCP after the start of the immunosuppressive therapy was 127 (SD 128) days. Before treatment, the clinical and biological features of the two groups were similar, except for the mean lymphocyte count which was lower in the PCP group than in the control group (1060/mm3 v 1426/mm3; p = 0.04). During treatment, both groups were lymphopenic. There was a significant difference between the lowest absolute lymphocyte count in each group (244/mm3 in the PCP group v 738/mm3 in the control group; p = 0.001). During the first three months of treatment, the lymphocyte count was less than 600/mm3 at least once in 10 of the 12 patients in the PCP group and in 11 of the 32 patients in the control group (p < 0.01). The mean cumulative dose of cyclophosphamide was greater in the PCP group than in the control group at the end of both the second (1.55 mg/kg/day v 0.99 mg/kg/day; p = 0.05) and the third (1.67 mg/kg/day v 0.97 mg/kg/day; p = 0.03) months. However, in multivariate analysis, the only two factors independently and significantly associated with the occurrence of PCP were the pretreatment lymphocyte count (p = 0.018) and the lymphocyte count three months after the start of the immunosuppressive treatment (p = 0.014).

CONCLUSIONS

The severity of lymphocytopenia before and during immunosuppressive treatment is the factor best associated with PCP in WG.

摘要

目的

确定与韦格纳肉芽肿(WG)患者发生卡氏肺孢子虫肺炎(PCP)相关的因素。

方法

我们回顾性比较了一组12例患有WG和PCP的患者(PCP组)与同期在相同中心随访的32例无PCP的WG患者(对照组)。

结果

免疫抑制治疗开始后PCP发病的平均延迟时间为127(标准差128)天。治疗前,两组的临床和生物学特征相似,但PCP组的平均淋巴细胞计数低于对照组(1060/mm³对1426/mm³;p = 0.04)。治疗期间,两组均出现淋巴细胞减少。每组最低绝对淋巴细胞计数之间存在显著差异(PCP组为244/mm³,对照组为738/mm³;p = 0.001)。在治疗的前三个月,PCP组12例患者中有10例、对照组32例患者中有11例淋巴细胞计数至少有一次低于600/mm³(p < 0.01)。在第二个月(1.55 mg/kg/天对0.99 mg/kg/天;p = 0.05)和第三个月(1.67 mg/kg/天对0.97 mg/kg/天;p = 0.03)末,PCP组环磷酰胺的平均累积剂量均高于对照组。然而,在多变量分析中,与PCP发生独立且显著相关的仅有的两个因素是治疗前淋巴细胞计数(p = 0.018)和免疫抑制治疗开始三个月后的淋巴细胞计数(p = 0.014)。

结论

免疫抑制治疗前及治疗期间淋巴细胞减少的严重程度是与WG患者发生PCP最相关的因素。

相似文献

5
[Pneumocystis pneumonia among patients with systemic diseases].[全身性疾病患者中的肺孢子菌肺炎]
Presse Med. 2009 Feb;38(2):251-9. doi: 10.1016/j.lpm.2008.11.004. Epub 2008 Dec 4.

引用本文的文献

1
pneumonia in non-HIV patients: need for a more extended prophylaxis.非HIV患者的肺炎:需要更广泛的预防措施。
Front Med (Lausanne). 2024 Jun 26;11:1414092. doi: 10.3389/fmed.2024.1414092. eCollection 2024.
10
Infection Risk and Safety of Corticosteroid Use.使用皮质类固醇的感染风险与安全性
Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x. doi: 10.1016/j.rdc.2015.08.004. Epub 2015 Oct 24.

本文引用的文献

5
Infectious complications of cyclophosphamide treatment for vasculitis.
Arthritis Rheum. 1989 Jan;32(1):45-53. doi: 10.1002/anr.1780320108.
7
Wegener granulomatosis: an analysis of 158 patients.韦格纳肉芽肿病:158例患者分析
Ann Intern Med. 1992 Mar 15;116(6):488-98. doi: 10.7326/0003-4819-116-6-488.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验